Get notified when CATX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPerspective Therapeutics presents interim Phase 1/2a data for lead cancer drug VMT-α-NET
Filed April 20, 2026 · Period ending April 18, 2026 · ~1 min read
Key Changes
-
high
Company disclosed interim results from Phase 1/2a trial of VMT-α-NET for advanced neuroendocrine tumors at major AACR 2026 cancer research conference, providing first public look at efficacy and safety data for its lead drug candidate.
Item 8.01 verify on EDGAR → -
high
Issued press release on April 20 detailing the clinical trial data, offering management commentary on results and likely influencing near-term stock performance and investor assessment of commercial potential.
Item 8.01 verify on EDGAR → -
medium
Updated corporate presentation to reflect new trial data and current pipeline status, providing investors with refreshed strategic positioning and development timelines.
Item 8.01 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade CATX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify